Company Description
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.
The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions.
Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services.
It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
| Country | Netherlands |
| Founded | 1986 |
| IPO Date | Jun 28, 1996 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 5,967 |
| CEO | Thierry Bernard |
Contact Details
Address: Hulsterweg 82 Pl Venlo, P7 5912 Netherlands | |
| Phone | 31-77-35566-00 |
| Website | qiagen.com |
Stock Details
| Ticker Symbol | QGEN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001015820 |
| CUSIP Number | N72482123 |
| ISIN Number | NL0015001WM6 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Thierry Bernard | Chief Executive Officer, MD and Member of Management Board |
| Dr. Roland Sackers | Chief Financial Officer, MD and Member of Management Board |
| Antonio Santos | Senior Vice President and Head of Global Operations |
| John Gilardi | Vice President of Corporate Communications and Investor Relations |
| Stephany Foster | Senior Vice President and Head of Human Resources |
| Dr. Thomas Schweins | Senior Vice President of Life Science Business Area |
| Dr. Thomas Theuringer | Senior Director and Head of External Communications |
| Jean-Pascal Viola | Senior Vice President and Head of Molecular Diagnostics Business Area |
| Dr. Jonathan G. Sheldon Ph.D. | Senior Vice President of Qiagen Digital Insights Business Area |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 11, 2024 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Mar 11, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | 6-K | Report of foreign issuer |
| Jan 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 23, 2024 | 6-K | Report of foreign issuer |
| Jan 8, 2024 | 6-K | Report of foreign issuer |
| Dec 6, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 1, 2023 | 6-K | Report of foreign issuer |
| Nov 1, 2023 | 6-K | Report of foreign issuer |